| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Prothrombin (Factor II) 20210G>A Mutation Analysis
Test CodeCPT Codes
<p>81240</p>
Preferred Specimen
Specimen Type: Whole blood
Collection Container/Type
Preferred: Lavender top (EDTA)
Acceptable: Royal blue-top (EDTA) plastic trace element blood collection tube, Yellow top (ACD), Green top (Sodium heparin), Green top (Lithium heparin)
Specimen Volume: 5 mL
Minimum Volume
3 mL
Specimen Stability
Room temperature: 8 days
Refrigerated: 8 days
Frozen: 30 days
Methodology
Polymerase Chain Reaction and Detection
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Report Available
4-5 days
Limitations
If this mutation is not found by the testing procedure, it does not mean that the risk of carrying or developing deep vein thrombosis is not present. It simply means that this specific mutation has not been found, although other mutations may be present. It is also possible that such a patient may have secondary deep vein thrombosis due to non-genetic causes that would not be detected by this test. A person with one copy of the mutation has an approximate 3-fold increase in risk for venous thrombosis. The increase in risk for a person with two copies of the mutation is not known.
Performing Laboratory
Polymerase Chain Reaction and Detection
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Last Updated: February 16, 2023